Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable results in many hematological malignancies. In addition to CAR-T, CAR-Natural Killer (NK) cell therapy has recently attracted attention with higher feasibility and better cytotoxicity. As of June 2023, there are six approved CAR-T products, and many more in the pipeline of clinical development However, the success of CAR-immune cell therapeutics in solid tumors is challenged by the tumor antigen heterogeneity, impaired transport and infiltration of CAR-immune cells, and suppression of the tumor microenvironment. Fortunately, promising results were observed when combining CAR-based cell therapies with other drugs such as immune checkpoint inhibitors.
Preclinical assessment of CAR-T and CAR-NK cell function, including direct tumor destruction, cytokine production, CAR-immune cell persistence, and therapy-related tumor microenvironment changes, is typically performed in different types of animal models. Creative Biolabs provides immunocompromised and immunocompetent models for functional assessment of CAR-immune cell products, as well as expert insights to design and plan treatment strategies using these models.
Efficacy studies
Preclinical safety evaluation
Creative Biolabs believes that the field of CAR-based cell therapies is very promising and will lead to validated and personalized therapeutic options in the future. Therefore, we also offer one-stop CAR-T and CAR-NK therapeutic development services, specializing in high-affinity scFv generation, CAR design and construction, as well as in vitro CAR-T/NK assays.
Questions, solutions, quotes-contact us!
For Research Use Only.